Literature DB >> 20208537

Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28.

Daniela Di Bella1, Federico Lazzaro, Alfredo Brusco, Massimo Plumari, Giorgio Battaglia, Annalisa Pastore, Adele Finardi, Claudia Cagnoli, Filippo Tempia, Marina Frontali, Liana Veneziano, Tiziana Sacco, Enrica Boda, Alessandro Brussino, Florian Bonn, Barbara Castellotti, Silvia Baratta, Caterina Mariotti, Cinzia Gellera, Valentina Fracasso, Stefania Magri, Thomas Langer, Paolo Plevani, Stefano Di Donato, Marco Muzi-Falconi, Franco Taroni.   

Abstract

Autosomal dominant spinocerebellar ataxias (SCAs) are genetically heterogeneous neurological disorders characterized by cerebellar dysfunction mostly due to Purkinje cell degeneration. Here we show that AFG3L2 mutations cause SCA type 28. Along with paraplegin, which causes recessive spastic paraplegia, AFG3L2 is a component of the conserved m-AAA metalloprotease complex involved in the maintenance of the mitochondrial proteome. We identified heterozygous missense mutations in five unrelated SCA families and found that AFG3L2 is highly and selectively expressed in human cerebellar Purkinje cells. m-AAA-deficient yeast cells expressing human mutated AFG3L2 homocomplex show respiratory deficiency, proteolytic impairment and deficiency of respiratory chain complex IV. Structure homology modeling indicates that the mutations may affect AFG3L2 substrate handling. This work identifies AFG3L2 as a novel cause of dominant neurodegenerative disease and indicates a previously unknown role for this component of the mitochondrial protein quality control machinery in protecting the human cerebellum against neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20208537     DOI: 10.1038/ng.544

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  47 in total

Review 1.  AAA+ proteins and substrate recognition, it all depends on their partner in crime.

Authors:  David A Dougan; Axel Mogk; Kornelius Zeth; Kürsad Turgay; Bernd Bukau
Journal:  FEBS Lett       Date:  2002-10-02       Impact factor: 4.124

2.  Characterization of mutants of the Escherichia coli AAA protease, FtsH, carrying a mutation in the central pore region.

Authors:  Takashi Okuno; Kunitoshi Yamanaka; Teru Ogura
Journal:  J Struct Biol       Date:  2006-03-06       Impact factor: 2.867

3.  Haploinsufficiency of AFG3L2, the gene responsible for spinocerebellar ataxia type 28, causes mitochondria-mediated Purkinje cell dark degeneration.

Authors:  Francesca Maltecca; Raffaella Magnoni; Federica Cerri; Gregory A Cox; Angelo Quattrini; Giorgio Casari
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

4.  Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families.

Authors:  Alfredo Brusco; Cinzia Gellera; Claudia Cagnoli; Alessandro Saluto; Alessia Castucci; Chiara Michielotto; Vincenza Fetoni; Caterina Mariotti; Nicola Migone; Stefano Di Donato; Franco Taroni
Journal:  Arch Neurol       Date:  2004-05

Review 5.  Pathways to motor incoordination: the inherited ataxias.

Authors:  Franco Taroni; Stefano DiDonato
Journal:  Nat Rev Neurosci       Date:  2004-08       Impact factor: 34.870

6.  Preparation of respiratory chain complexes from Saccharomyces cerevisiae wild-type and mutant mitochondria : activity measurement and subunit composition analysis.

Authors:  Claire Lemaire; Geneviève Dujardin
Journal:  Methods Mol Biol       Date:  2008

Review 7.  Spinocerebellar ataxias: an update.

Authors:  Bing-wen Soong; Henry L Paulson
Journal:  Curr Opin Neurol       Date:  2007-08       Impact factor: 5.710

8.  Variable and tissue-specific subunit composition of mitochondrial m-AAA protease complexes linked to hereditary spastic paraplegia.

Authors:  Mirko Koppen; Metodi D Metodiev; Giorgio Casari; Elena I Rugarli; Thomas Langer
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

9.  The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria.

Authors:  Mark Nolden; Sarah Ehses; Mirko Koppen; Andrea Bernacchia; Elena I Rugarli; Thomas Langer
Journal:  Cell       Date:  2005-10-21       Impact factor: 41.582

10.  Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease.

Authors:  G Casari; M De Fusco; S Ciarmatori; M Zeviani; M Mora; P Fernandez; G De Michele; A Filla; S Cocozza; R Marconi; A Dürr; B Fontaine; A Ballabio
Journal:  Cell       Date:  1998-06-12       Impact factor: 41.582

View more
  118 in total

Review 1.  Recent advances in the genetics of cerebellar ataxias.

Authors:  Anna Sailer; Henry Houlden
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

2.  Defective mitochondrial mRNA maturation is associated with spastic ataxia.

Authors:  Andrew H Crosby; Heema Patel; Barry A Chioza; Christos Proukakis; Kay Gurtz; Michael A Patton; Reza Sharifi; Gaurav Harlalka; Michael A Simpson; Katherine Dick; Johanna A Reed; Ali Al-Memar; Zofia M A Chrzanowska-Lightowlers; Harold E Cross; Robert N Lightowlers
Journal:  Am J Hum Genet       Date:  2010-10-21       Impact factor: 11.025

3.  Electron cryomicroscopy structure of a membrane-anchored mitochondrial AAA protease.

Authors:  Sukyeong Lee; Steffen Augustin; Takashi Tatsuta; Florian Gerdes; Thomas Langer; Francis T F Tsai
Journal:  J Biol Chem       Date:  2010-12-08       Impact factor: 5.157

4.  Loss of the m-AAA protease subunit AFG₃L₂ causes mitochondrial transport defects and tau hyperphosphorylation.

Authors:  Arun Kumar Kondadi; Shuaiyu Wang; Sara Montagner; Nikolay Kladt; Anne Korwitz; Paola Martinelli; David Herholz; Michael J Baker; Astrid C Schauss; Thomas Langer; Elena I Rugarli
Journal:  EMBO J       Date:  2014-03-28       Impact factor: 11.598

Review 5.  Using the shared genetics of dystonia and ataxia to unravel their pathogenesis.

Authors:  Esther A R Nibbeling; Cathérine C S Delnooz; Tom J de Koning; Richard J Sinke; Hyder A Jinnah; Marina A J Tijssen; Dineke S Verbeek
Journal:  Neurosci Biobehav Rev       Date:  2017-01-28       Impact factor: 8.989

6.  Mutant huntingtin inhibits the mitochondrial unfolded protein response by impairing ABCB10 mRNA stability.

Authors:  Zixing Fu; Fang Liu; Chunyue Liu; Beifang Jin; Yueqing Jiang; Mingliang Tang; Xin Qi; Xing Guo
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-02-23       Impact factor: 5.187

Review 7.  Mitochondrial protein quality control in health and disease.

Authors:  Michael J Baker; Catherine S Palmer; Diana Stojanovski
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  Non-syndromic isolated dominant optic atrophy caused by the p.R468C mutation in the AFG3 like matrix AAA peptidase subunit 2 gene.

Authors:  Davide Colavito; Veronica Maritan; Agnese Suppiej; Elda Del Giudice; Monica Mazzarolo; Stefania Miotto; Sofia Farina; Maurizio Dalle Carbonare; Stefano Piermarocchi; Alberta Leon
Journal:  Biomed Rep       Date:  2017-09-22

9.  Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy.

Authors:  Stephan Klebe; Christel Depienne; Sylvie Gerber; Georges Challe; Mathieu Anheim; Perrine Charles; Estelle Fedirko; Elodie Lejeune; Julien Cottineau; Alfredo Brusco; Hélène Dollfus; Patrick F Chinnery; Cecilia Mancini; Xavier Ferrer; Guilhem Sole; Alain Destée; Jean-Michel Mayer; Bertrand Fontaine; Jérôme de Seze; Michel Clanet; Elisabeth Ollagnon; Philippe Busson; Cécile Cazeneuve; Giovanni Stevanin; Josseline Kaplan; Jean-Michel Rozet; Alexis Brice; Alexandra Durr
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

Review 10.  Mitochondrial Diseases Part II: Mouse models of OXPHOS deficiencies caused by defects in regulatory factors and other components required for mitochondrial function.

Authors:  Luisa Iommarini; Susana Peralta; Alessandra Torraco; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.